BLA 761113 · Sanofi Aventis US
Sarclisa
Isatuximab-Irfc · Injection · CD38-directed Cytolytic Antibody
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Mar 2, 2020
Approved uses
6
Original approval plus efficacy supplements
Registered trials
107
21 Phase 3, 30 recruiting
FAERS reports
5,800
5,382 serious, 767 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 7, 2026.
SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). SARCLISA is a CD38-directed cytolytic antibody indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). ( 1 )
Mechanism: Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on the surface of hematopoietic and tumor cells, including multiple myeloma cells. Isatuximab-irfc induces apoptosis of tumor cells and activation of immune effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC). Isatuximab-irfc inhibits the ADP-ribosyl cyclase activity of CD38. Isatuximab-irfc can activate natural killer (NK) cells in the absence of CD38-positive target tumor cells and...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 25, 2024 Supplement 11 · Efficacy OrphanLabelLetter
- Oct 25, 2024 Supplement 12 · Efficacy OrphanLabelLetter
- Sep 20, 2024 Supplement 14 · Efficacy · priority review OrphanLabelLetter
- Nov 1, 2023 Supplement 9 · Efficacy OrphanLabelLetter
- Mar 31, 2021 Supplement 3 · Efficacy LabelLetter
- Mar 2, 2020 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
- SARCLISA · ISATUXIMAB-IRFC 500MG/25ML (20MG/ML) · INJECTABLE, INJECTION · Prescription
- SARCLISA · ISATUXIMAB-IRFC 100MG/5ML (20MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Isatuximab" as an intervention, any sponsor and status, largest first.
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic LeukemiaPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06860269 · 1,200 participants (planned) · Start May 6, 2025 · Primary completion Mar 15, 2035
Drug: Randomization + Blinatumomab + chemotherapy; Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone and 1 more · For: Acute Lymphoblastic Leukemia
Sites: Paris, France
- MInimal Residual Disease Adapted StrategyPivotal-lookingActive, not recruiting
Intergroupe Francophone du MyelomeResearch network
NCT04934475 · 791 participants · Start Dec 8, 2021 · Primary completion Sep 30, 2024
Drug: Isatuximab · For: Multiple Myeloma
Sites: Brussels, Belgium; Charleroi, Belgium; Haine-Saint-Paul, Belgium · 73 sites in all
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07903506 · 750 participants (planned) · Start Feb 2027 · Primary completion Mar 2039
Drug: Anitocabtagene Autoleucel; Isatuximab and 6 more · For: Newly Diagnosed Multiple Myeloma
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07764978 · 750 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 11, 2029
Drug: AZD0120; Daratumumab and 6 more · For: Newly Diagnosed Multiple Myeloma
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 124 sites in all
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMPivotal-lookingRecruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07624513 · 720 participants (planned) · Start Aug 31, 2026 · Primary completion Oct 1, 2033
Drug: Isatuximab; Iberdomide and 4 more · For: Multiple Myeloma
Sites: Boston, Massachusetts · 3 sites in all
- Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)Pivotal-lookingActive, not recruiting
University of Heidelberg Medical CenterAcademic, hospital or other
NCT03617731 · 662 participants · Start Oct 18, 2018 · Primary completion Jun 2028
Drug: Lenalidomide; Bortezomib and 2 more · For: Multiple Myeloma
Sites: Aachen, Germany; Bad Saarow, Germany; Berlin, Germany · 72 sites in all
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Canadian Cancer Trials GroupResearch network
NCT06182774 · 570 participants (planned) · Start Apr 10, 2024 · Primary completion Jan 31, 2032
Drug: Daratumumab; Lenalidomide and 2 more · For: Multiple Myeloma
Sites: Edmonton, Canada; Kelowna, Canada; Vancouver, Canada · 31 sites in all
- SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05405166 · 531 participants · Start Jun 23, 2022 · Primary completion Nov 6, 2024
Drug: Isatuximab IV; Isatuximab SC and 7 more · For: Plasma Cell Myeloma Recurrent
Sites: Aurora, Colorado; Jacksonville, Florida; Plantation, Florida · 128 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia524
- plasma cell myeloma408
- pneumonia386
- thrombocytopenia330
- covid-19306
- pyrexia295
- anaemia284
- infusion related reaction260
- diarrhoea251
- off label use242
- dyspnoea210
- nausea172
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 20 |
| 2019 | 62 |
| 2020 | 353 |
| 2021 | 680 |
| 2022 | 1,138 |
| 2023 | 1,302 |
| 2024 | 814 |
| 2025 | 718 |
| 2026 | 707 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sarclisa (Isatuximab-Irfc)
2024 spending
$6.0M
Beneficiaries
74
601 claims
Per beneficiary
$81,053
$155.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $256,912 |
| 2021 | $1,905,676 |
| 2022 | $3,413,637 |
| 2023 | $3,679,042 |
| 2024 | $5,997,930 |
Part B: Sarclisa (Isatuximab-Irfc) · HCPCS J9227
2024 spending
$67.9M
Beneficiaries
1,082
10,691 claims
Per beneficiary
$62,799
2024 ASP limit $77.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,821,763 |
| 2021 | $28,633,447 |
| 2022 | $42,512,757 |
| 2023 | $54,190,478 |
| 2024 | $67,948,017 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, et al. · Nat Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Ailawadhi S, pička I, Spencer A, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Perrot A, Lambert J, Hulin C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.